[HTML][HTML] Immunotherapy: reshape the tumor immune microenvironment

B Lv, Y Wang, D Ma, W Cheng, J Liu, T Yong… - Frontiers in …, 2022 - frontiersin.org
Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …

[HTML][HTML] LAG-3: from molecular functions to clinical applications

T Maruhashi, D Sugiura, I Okazaki… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
To prevent the destruction of tissues owing to excessive and/or inappropriate immune
responses, immune cells are under strict check by various regulatory mechanisms at …

[HTML][HTML] Immunotherapy in colorectal cancer: rationale, challenges and potential

K Ganesh, ZK Stadler, A Cercek… - Nature reviews …, 2019 - nature.com
Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a …

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

JA Fraietta, SF Lacey, EJ Orlando, I Pruteanu-Malinici… - Nature medicine, 2018 - nature.com
Tolerance to self-antigens prevents the elimination of cancer by the immune system,. We
used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and …

[PDF][PDF] Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3

J Wang, MF Sanmamed, I Datar, TT Su, L Ji, J Sun… - Cell, 2019 - cell.com
Summary Lymphocyte-activation gene 3 (LAG-3) is an immune inhibitory receptor, with
major histocompatibility complex class II (MHC-II) as a canonical ligand. However, it remains …

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

S Rafiq, OO Yeku, HJ Jackson, TJ Purdon… - Nature …, 2018 - nature.com
The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding
tumors can be enhanced by administering the cells in combination with immune checkpoint …

LAG3 associates with TCR–CD3 complexes and suppresses signaling by driving co-receptor–Lck dissociation

C Guy, DM Mitrea, PC Chou, J Temirov, KM Vignali… - Nature …, 2022 - nature.com
LAG3 is an inhibitory receptor that is highly expressed on exhausted T cells. Although LAG3-
targeting immunotherapeutics are currently in clinical trials, how LAG3 inhibits T cell function …

[HTML][HTML] The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application

JL Huo, YT Wang, WJ Fu, N Lu, ZS Liu - Frontiers in immunology, 2022 - frontiersin.org
LAG-3, a type of immune checkpoint receptor protein belonging to the immunoglobulin
superfamily, is confirmed to be expressed on activated immune cells, mainly including …

[HTML][HTML] Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial

RW Naumann, A Hollebecque, T Meyer… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal,
or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial - PMC Back to Top …

[PDF][PDF] Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

AC Anderson, N Joller, VK Kuchroo - Immunity, 2016 - cell.com
Co-inhibitory receptors, such as CTLA-4 and PD-1, have an important role in regulating T
cell responses and have proven to be effective targets in the setting of chronic diseases …